New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Does GLP-1RA use impact the risk of thyroid cancer? GLP-1RAs are highly effective medications used to treat T2D and obesity while simultaneously conferring protection against cardiovascular ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The weight loss drug "glucagon-like peptide-1 receptor agonists (GLP-1RA)" is showing effectiveness in various diseases and is gaining significant attention worldwide. However, not all GLP-1-based ...

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset MET-097i through a Phase III trial.

Efruxifermin (EFX) with GLP-1RA significantly reduces hepatic fat fraction and improves fibrosis in MASH and T2D patients. The study involved 31 patients over 12 weeks, showing EFX enhances GLP ...

Glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs like Ozempic and Wegovy are called “miracle drugs” by some pharmacists for their ability to help those with diabetes to lose weight. The drugs ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...